4 assets in Myxoid Liposarcoma

Therapeutic assets addressing Myxoid Liposarcoma, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Cyclophosphamide Myxoid Liposarcoma	Medigene AG	P2	B (63)
Pembrolizumab Myxoid Liposarcoma	Valo Therapeutics Oy	P2	B (63)
MDG1015 Myxoid Liposarcoma	Medigene AG	P1	CC (43)
Pepticrad-1 Myxoid Liposarcoma	Valo Therapeutics Oy	P1	CC (43)